Iradimed Corp.

IRMD

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001325618

A

strongest fifth of 370 graded peers in healthcare

rank 10 of 370; percentile 2.4; sampling error 2.5 points; lower is stronger

A B C D E

A, the bull



Scoreboard	
Profitability	B percentile 31.3
Solvency	A percentile 13.6
Growth and financing	B/C percentile 38.1
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $108.8M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: dilution, distress, fortress balance sheet
Inputs computable	9 of 14
Graded from	filings received through Mar 6, 2026 228 days before the rescan; latest periodic filing 10-Q received Jul 31, 2026
Last close	$87.53 2026-10-19; market equity $1.1B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 6, 2026

IRADIMED CORPORATION ("IRadimed", the "Company," "we," "us," "our" or similar terms) develops, manufactures, markets and distributes Magnetic Resonance Imaging ("MRI") compatible medical devices and related accessories, disposables and services relating to them. We were originally incorporated in Oklahoma under the name IRI Development, Inc. in 1992, and we merged our Oklahoma corporation into the newly formed Delaware corporation, IRADIMED CORPORATION, in April 2014. We are the only known provider of a non-magnetic intravenous ("IV") infusion pump system that is specifically designed to be safe for use during MRI procedures and operates dependably in magnetic fields up to 15,000 gauss.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight


Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 31.3						
Gross profitability	59.1%	32.3%		17.3	371	2025-12-31
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing					
Accruals ratio	(2.4%)	(6.6%)	74.6	812	2025-12-31
Gross margin stability, five years	0.3 pts	2.8 pts	2.1	242	2025-12-31
Solvency, sleeve percentile 13.6					
Twelve-month failure probability	not computable	0.06%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	14.84	(0.30)	4.8	757	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	7.98x	2.96x	22.4	840	2025-12-31
Growth and financing, sleeve percentile 38.1					
Revenue growth, three-year compound	16.3%	10.1%	37.3	414	2025-12-31
Free cash flow growth, three-year compound	23.1%	10.9%	37.9	96	2025-12-31
Reinvestment rate	52.6%	37.1%	43.7	104	2025-12-31
Asset growth, three years	8.4%	2.1%	33.5	705	2025-12-31
Net share issuance, one year	not computable	2.5%			
prior share count is 181 days earlier					

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
5	Mimedx Group, Inc. (MDXG)	1.1	A	fortress balance sheet
6	Harmony Biosciences Holdings, Inc. (HRMY)	1.4	A	fortress balance sheet
7	BeOne Medicines Ltd. (ONC)	1.6	A	fortress balance sheet
8	Progyny, Inc. (PGNY)	1.9	A	
9	Exelixis, Inc. (EXEL)	2.2	A	fortress balance sheet
10	Iradimed Corp. (IRMD)	2.4	A	
11	Castle Biosciences Inc. (CSTL)	2.7	A	fortress balance sheet
12	Penumbra Inc. (PEN)	3.0	A	
13	Lemaitre Vascular Inc. (LMAT)	3.3	A	
14	Corcept Therapeutics Inc. (CORT)	3.5	A	fortress balance sheet
15	Electromed, Inc. (ELMD)	3.8	A	fortress balance sheet

What the price implies

at the 2026-10-19 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	23.1%	8.0%	61
Distance from 52-week high	(16.6%)	(31.9%)	70
EBIT to enterprise value	not computable	(1.6%)	
Free cash flow yield	1.5%	(1.0%)	63

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Book value to price	0.09	0.28	25
Sales to price	0.07	0.31	21
Composite equity issuance, five years	(5.8%)	20.3%	19
Relative strength against the sector, log excess return	(0.00)	(0.13)	61

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$59.1M
Operating cash flow, four quarters	$27.1M
Months of runway	not finite
Days since last periodic filing	81 (10-Q received Jul 31, 2026)
Median daily dollar volume, 63 sessions	$8.9M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$64.3M	2025-12-31	2026-03-06	10-K	26-024691
2	assets	us-gaap:Assets	$108.8M	2025-12-31	2026-03-06	10-K	26-024691
3	net income	us-gaap:NetIncomeLoss	$22.5M	2025-12-31	2026-03-06	10-K	26-024691
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$24.9M	2025-12-31	2026-03-06	10-K	26-024691
5	assets	us-gaap:Assets	$98.3M	2024-12-31	2026-03-06	10-K	26-024691
6	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$83.8M	2025-12-31	2026-03-06	10-K	26-024691
7	gross profit	us-gaap:GrossProfit	$56.4M	2024-12-31	2026-03-06	10-K	26-024691
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$73.2M	2024-12-31	2026-03-06	10-K	26-024691
9	gross profit	us-gaap:GrossProfit	$50.2M	2023-12-31	2025-09-03	10-K/A	25-011853
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$65.6M	2023-12-31	2025-09-03	10-K/A	25-011853
11	gross profit	us-gaap:GrossProfit	$41.3M	2022-12-31	2024-03-01	10-K	24-002235
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$53.3M	2022-12-31	2024-03-01	10-K	24-002235
13	gross profit	us-gaap:GrossProfit	$32.0M	2021-12-31	2023-03-02	10-K	23-028003
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$41.8M	2021-12-31	2023-03-02	10-K	23-028003
15	current assets	us-gaap:AssetsCurrent	$81.2M	2025-12-31	2026-03-06	10-K	26-024691
16	current liabilities	us-gaap:LiabilitiesCurrent	$10.2M	2025-12-31	2026-03-06	10-K	26-024691
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$64.2M	2025-12-31	2026-03-06	10-K	26-024691
18	operating income	us-gaap:OperatingIncomeLoss	$26.1M	2025-12-31	2026-03-06	10-K	26-024691
19	book equity	us-gaap:StockholdersEquity	$94.6M	2025-12-31	2026-03-06	10-K	26-024691
20	liabilities	us-gaap:Liabilities	$14.2M	2025-12-31	2026-03-06	10-K	26-024691
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$7.8M	2025-12-31	2026-03-06	10-K	26-024691
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$25.6M	2024-12-31	2026-03-06	10-K	26-024691
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$8.0M	2024-12-31	2026-03-06	10-K	26-024691
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$13.5M	2023-12-31	2025-09-03	10-K/A	25-011853
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$7.4M	2023-12-31	2025-09-03	10-K/A	25-011853
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$10.0M	2022-12-31	2024-03-01	10-K	24-002235

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$823,019	2022-12-31	2024-03-01	10-K	24-002235
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$1.2M	2025-12-31	2026-03-06	10-K	26-024691
29	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$28.4M	2025-12-31	2026-03-06	10-K	26-024691
30	income tax	us-gaap:IncomeTaxExpenseBenefit	$5.9M	2025-12-31	2026-03-06	10-K	26-024691
31	current assets	us-gaap:AssetsCurrent	$75.2M	2024-12-31	2026-03-06	10-K	26-024691
32	current liabilities	us-gaap:LiabilitiesCurrent	$8.5M	2024-12-31	2026-03-06	10-K	26-024691
33	assets	us-gaap:Assets	$92.2M	2023-12-31	2025-09-03	10-K/A	25-011853
34	assets	us-gaap:Assets	$85.5M	2022-12-31	2024-03-01	10-K	24-002235
35	shares outstanding	dei:EntityCommonStockSharesOutstanding	12,782,566	2026-02-28	2026-03-06	10-K	26-024691
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	12,715,072	2025-08-31	2025-09-03	10-K/A	25-011853

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.